EXELIXIS INC

Exelixis’s oncology focus & cabozantinib growth: Discover how its CABOMETYX and new Handa capsule are driving $13.3B market cap and future pharma partnerships.

Exelixis faces an “Underperform” downgrade as analysts flag valuation overreach and missing FDA catalysts, while the growing CSPC market offers only untapped potential.

Exelixis Inc. gains institutional backing and rides a projected rise in rhabdomyosarcoma market, with its Cabozantinib partnership poised to boost growth.

Exelixis Inc. reports mixed quarterly results, beating EPS expectations but falling short on revenue, amidst a challenging biotech industry landscape.

Exelixis Inc. reported a mixed quarter with declining revenue and earnings, but a significant strategic milestone with EU approval for its cancer treatment CABOMETYX.

Exelixis Inc.’s stock price has surged following promising trial results for its colorectal cancer drug, zanzalintinib, with analysts predicting significant future growth and sales potential.

Exelixis Inc’s stock price surges 14% after a pivotal cancer drug trial shows a notable survival benefit, positioning the biotech company as a leader in the industry.

Exelixis Inc.’s stock price surged after a positive cancer trial result and analyst upgrades, boosting investor confidence in the biotechnology company’s future prospects.

Exelixis Inc’s stock has surged due to impressive financial results and strategic moves, solidifying its position as a leader in the biotechnology industry.

Exelixis Inc.’s stock price surged on May 14, 2025, following a strong Q1 performance and raised guidance, with several analysts increasing their price targets.